Pradaxa (dabigatran) was approved by the FDA in October 2010.  It is a blood thinner, meaning it is often prescribed to assist in reducing the risk of blood clots that are frequently associated with, in this case, atrial fibrillation. Atrial fibrillation often produces an irregular, rapid heart rhythm, which affects over 2 million people in America. It can increase the risk of blood clots, which may cause stroke if the clots travel to the brain. Pradaxa is manufactured by and marketed as easier to use than some blood-thinning drugs, requiring less monitoring.

Pradaxa is known as a direct thrombin inhibitor, and there is no known antidote for bleeding caused by this class of drug, unlike other blood thinners that can be treated with Vitamin K.  Some of the Pradaxa side effects include hemorrhaging, serious internal bleeding, and gastrointestinal bleeding, which may lead to a patient’s death. Since gaining FDA approval, Boehringer Ingelheim has acknowledged that there have been over 250 Pradaxa-related deaths.

Regarding Pradaxa’s side effects, internal bleeding and hemorrhaging can be difficult to detect. Consumers should look for unusual bruising, pink or brown urine, coughing up blood, swollen joints, and any other problems related to bleeding.  If you notice any of these symptoms, contact your doctor right away.

If you or someone you know has taken Pradaxa and developed hemorrhaging, serious internal bleeding, gastrointestinal bleeding or died while taking Pradaxa, you should speak with us to learn more about your legal rights.